Endometrial cancer is the fourth most common female malignancy. This chapter provides a synopsis of the published and continuing clinical research in several controversial areas, from initial surgical management through adjuvant systemic therapy to the management of recurrent disease. While surgery alone is adequate treatment for many women with low-risk endometrial cancers, it is clear that a substantial minority of cases are at significant risk of disease recurrence. The management of recurrent endometrial cancer can be complex and requires the assessment of several factors including the site(s) of disease recurrence, histological grade and the patient's performance status, comorbidities and wishes. Three uncommon histological sub-types account for 10-15% of all endometrial carcinomas. Serous carcinomas, clear-cell carcinomas and carcinosarcomas differ in their clinical behaviour from endometrioid carcinomas as they are more likely to present at an advanced stage and consequently have poorer prognosis.